
Mitsui Chemicals
Tokyo Midtown Yaesu, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, 104-0028, Japan
Overview
Mitsui Chemicals is a leading manufacturer and supplier of value added specialty chemicals, plastics and materials for the automotive, healthcare, packaging, agricultural, building, and semiconductor and electronics markets. Combining advanced technologies and processing methods, we deliver high performance materials to you for use in the development of medications, packaging materials, automotive components, building materials and electronic parts and accessories.
- Total investments
- 5
- Lead investments
- 0
- Investments · 12mo
- 2
- Active investors
- 5
Sector focus
- Chemical
- Manufacturing
Investment portfolio
- Glydways
Participated · Series C · Apr 2026
Glydways builds autonomous electric Glydcars that operate on a two-metre-wide dedicated guideway called the Flow Network, designed to move up to 10,000 people per hour through lanes narrower than a parking space. The company says its system can be built at up to 90% lower cost than traditional rail while matching capacity, and emphasizes closed infrastructure to avoid safety issues tied to open-road autonomous vehicles. Founded in 2016 by Mark Seeger, Glydways is working on more than 20 projects globally and has begun construction on a public system in South Metro Atlanta. It has agreements for pilots in the UAE and plans additional pilots in the New York City area, with wider expansion planned for 2027. Glydways employs about 270 people and plans to double headcount over the next two years as it scales deployments.
- Monogusa
Participated · Series C · Oct 2025
Founded in 2016, Tokyo-based Monogusa develops and operates Monoxer, a memory-optimization platform that personalizes drills and repetition to improve long-term recall. The software was first adopted by cram schools and private institutions and is now expanding into public education systems, municipalities, and enterprise upskilling programs. Corporations use Monoxer to raise qualification-exam pass rates, onboard sales staff, and capture tacit knowledge in manufacturing, retail, leasing, and other operational settings. New features in development include automatic generation of learning content from internal manuals and data, as well as sector-specific enablement tools for skills transfer in construction and manufacturing. The company recently introduced "Monoxer Junior" for early childhood learning and plans a university student service that links study with career development, plus lifelong learning offerings for professionals. Capital from the Series C round will fund product development, marketing, hiring, and new business lines. Although no revenue or user figures were disclosed, management highlighted rapid adoption across both education and enterprise markets.
- RLWRLD
Participated · Seed · Apr 2025
RLWRLD is a physical AI company building robotics intelligence that collects and learns from on-site industrial data, enabling robots to understand their environments and make autonomous decisions. After completing initial technology verification, the firm is now running joint proof-of-concept (PoC) and RX (robotic transformation) projects with major Korean companies such as CJ Logistics and Lotte, and is expanding trials in Japan through partner Z Venture. Management states that real-world validation is critical and plans to officially release a robotics foundation model in the first half of 2026. Demand for its technology is rising amid East Asia’s labor shortages, driving interest from strategic partners that control large industrial sites. Financially, RLWRLD secured about US$15 million in a Seed 1 round and has now added roughly US$26 million in Seed 2 financing, bringing cumulative seed funding to approximately US$41 million. The fresh capital supports continued product development and broader global collaborations. Key backers include Headline Asia, CJ Logistics Corporation, Kakao Investment, LOTTE Ventures, Hanwha Asset Management, Mirae Asset·emart and Z Venture.
- Rege Nephro
Participated · Series B · Oct 2024
Rege Nephro is developing therapies for kidney disease and is advancing a clinical pipeline in the renal space. The company is preparing for clinical trials and is using interim financing to accelerate R&D and pipeline advancement. Its recent bridge financing is intended to extend cash runway and de-risk near-term development milestones ahead of a larger Series C. Rege Nephro says this capital raise is part of a longer-term strategy to strengthen its position in renal therapies. The company plans to pursue a Series C in autumn 2026 and beyond as it progresses clinical and development activities.
Team
Osamu Hashimoto
Chief Executive Officer
Atsushi Komoriya
Managing execuitive
Nakajima Hajime
Chief Financial Officer, Finance
Shintaro Maekawa
Scientific Project Lead
LinkedIn